R&D

Medica Korea Co., Ltd. established the MK Institute of Regenerative Medicine 'MIRM' in Jiphyeon-dong, Sejong-si in 2019 to focus on renewable medical research and development, and established an efficient development environment such as clean workplaces to study aseptic and biodegradable materials.

Sejong Research Institute
  • Sejong Research Institute

  • Starting with the development of biocompatible materials, we are preparing medical devices tailored to the needs of the convergence of regenerative materials, and we have established a real-time virus diagnosis system to ensure the safety of materials.

R&D Strategy
Securing new engines through research and development of renewable materials in an aging society
  • OECD average life expectancy is 81 years old, joint disease is increasing proportionally with aging
  • Diversification of regenerative treatment research using medical collagen
  • Applicable to various products such as joint treatment, wound and burn treatment
Product development tailored to needs Technical cooperation through strategic alliance
  • Expand and strengthen networks with domestic and foreign pharmaceutical companies, hospitals, animal medical centers, and university research institutes
  • Technical cooperation with specialized institutions for regeneration research, product development tailored to needs
R&D Achievement
Secure competitiveness
  • Patent : 1 application, 1 registration
Applied product Patent name Application number Registration number
Atelocollagen Manufacturing method of high-yield collagen with off-flavor removed 10-2019-0161751 10-2155509
Method for enhancing yield or content of collagen using pH titration 10-2021-0087970
  • Atelocollagen virus process validation (International standard)


Signed MOU (5 cases)
2022.06 Signed a business agreement to build a smart factory at Konyang University
2022.03 Signed an exclusive supply business agreement to expand the raw material market for medical devices at Agathonbio
2022.01 Signed a business agreement for pharmaceutical technology-based peptide material development at Incospharm
2021.08 Signed a business agreement for medical device development and diagnosis business at Ieum Animal Medical Center
2019.12 Signed a business agreement for joint development of material medical devices in Nanding, China


Assignments (8 cases)
1 Assignment name 2022 World Class Plus Project - R&D for clinical trial entry and successful commercialization of KDS2010, a non-psychotropic obesity drug
Department Ministry of Trade, Industry and Energy(MOTIE)
Date 2022. 06. 01- 2025. 12. 31
2 Assignment name Fostering regional specialized industries + (R&D) Fostering regional key industries - Development of high-purity production technology for biodegradable polymer materials for implantable medical devices
Department Ministry of SMEs and Startups(MSS)
Date 2020. 09. 01 - 2021. 12. 31
3 Assignment name Biomedical active material base construction project - medical collagen virus confirmation test
Department Intelligent Synthetic Biology Center
Date 2022. 06 – 2022. 10
4 Assignment name Biomedical active material base establishment project - Technology consulting for the development of diagnostic kits for degenerative brain diseases
Department Intelligent Synthetic Biology Center
Date 2022. 06 – 2022. 10
5 Assignment name Biomedical active material foundation establishment project - Support for licensing of raw materials for health functional food for cognitive function improvement
Department Intelligent Synthetic Biology Center
Date 2022. 06 – 2022. 10
6 Assignment name Biomedical active material foundation establishment project - Virus stability test certification for biomaterial medical device filler development
Department Intelligent Synthetic Biology Center
Date 2021. 05. 01 - 2021. 12. 10
7 Assignment name Biomedical active material foundation establishment project - Material test analysis
Department Intelligent Synthetic Biology Center
Date 2020. 10. 01 – 2021. 12. 31
8 Assignment name Biomedical active material foundation establishment project - Prototype production of aptamer-based jensenoside separation purification column
Department Intelligent Synthetic Biology Center
Date 2020. 10. 01 – 2021. 12. 31
Product
Reagent

Atelocollagen TypeⅠ, from porcine

Atelocollagen Reagent 10ml

Biological source Porcine skin
Form Solution
Type Atelocollagen type I
Content 0.5mg/ml
Storage 2-8℃ For research use only

Atelocollagen Reagent 100ml

Biological source Porcine skin
Form Liquid
Type Atelocollagen type I
Content 0.5mg/ml
Storage 2-8℃ For research use only
Raw material

Consultation on specifications such as dosage form, content, quantity, etc. (*Inquire separately)